Experienced in Nodular Lymphocyte-Predominant Hodgkin Lymphoma (NLPHL)

Dr. Andrei R. Shustov

Hematology Oncology
825 Eastlake Avenue E, G3-200, 
Seattle, WA 
Accepting New Patients
Offers Telehealth
Experienced in Nodular Lymphocyte-Predominant Hodgkin Lymphoma (NLPHL)
825 Eastlake Avenue E, G3-200, 
Seattle, WA 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Andrei Shustov is a Hematologist Oncology provider in Seattle, Washington. Dr. Shustov is rated as an Experienced provider by MediFind in the treatment of Nodular Lymphocyte-Predominant Hodgkin Lymphoma (NLPHL). His top areas of expertise are Peripheral T-Cell Lymphoma, T-Cell Lymphoma, Anaplastic Large Cell Lymphoma, Bone Marrow Transplant, and Bone Marrow Aspiration. Dr. Shustov is currently accepting new patients.

His clinical research consists of co-authoring 96 peer reviewed articles and participating in 8 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Hematology Oncology
Licenses
Internal Medicine in WA
Languages Spoken
English
German
Portuguese
Russian
Ukrainian
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Anthem
  • EPO
  • HMO
  • POS
  • PPO
Premera
  • EPO
  • PPO

Locations

825 Eastlake Avenue E, G3-200, Seattle, WA 98109

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

8 Clinical Trials

A Phase 2 Multicenter Study of High Dose Chemotherapy With Autologous Stem Cell Transplant Followed by Maintenance Therapy With Romidepsin for the Treatment of T Cell Non-Hodgkin Lymphoma
A Phase 2 Multicenter Study of High Dose Chemotherapy With Autologous Stem Cell Transplant Followed by Maintenance Therapy With Romidepsin for the Treatment of T Cell Non-Hodgkin Lymphoma
Enrollment Status: Completed
Publish Date: October 09, 2025
Intervention Type: Other
Study Drugs: High Dose Chemotherapy, Autologous Stem Cell Transplant, Romidepsin
Study Phase: Phase 2
Phase II Study of Romidepsin Plus Lenalidomide for Patients With Previously Untreated PTCL
Phase II Study of Romidepsin Plus Lenalidomide for Patients With Previously Untreated PTCL
Enrollment Status: Active_not_recruiting
Publish Date: April 10, 2024
Intervention Type: Other, Drug
Study Drugs: Romidepsin, Lenalidomide
Study Phase: Phase 2
A Phase 1, Dose-Finding Study of Folotyn® (Pralatrexate Injection) Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) in Patients With Peripheral T-Cell Lymphoma (PTCL)
A Phase 1, Dose-Finding Study of Folotyn® (Pralatrexate Injection) Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) in Patients With Peripheral T-Cell Lymphoma (PTCL)
Enrollment Status: Completed
Publish Date: July 27, 2021
Intervention Type: Drug
Study Phase: Phase 1
A Phase 2, Open-Label Study Evaluating the Efficacy, Safety, Tolerability, and Pharmacodynamics of GS-9973 in Subjects With Relapsed or Refractory Hematologic Malignancies
A Phase 2, Open-Label Study Evaluating the Efficacy, Safety, Tolerability, and Pharmacodynamics of GS-9973 in Subjects With Relapsed or Refractory Hematologic Malignancies
Enrollment Status: Terminated
Publish Date: November 19, 2020
Intervention Type: Drug
Study Phase: Phase 2
A Phase II Study of Plitidepsin in Patients With Relapsed or Refractory Angioimmunoblastic T-cell Lymphoma
A Phase II Study of Plitidepsin in Patients With Relapsed or Refractory Angioimmunoblastic T-cell Lymphoma
Enrollment Status: Terminated
Publish Date: October 14, 2020
Intervention Type: Drug
Study Phase: Phase 2
A Phase 2, Single-Arm, Open-Label, Multicenter, Study of Folotyn® (Pralatrexate Injection) in Combination With Oral Leucovorin to Prevent or Reduce Mucositis in Patients With Hematological Malignancies Including PTCL and CTCL
A Phase 2, Single-Arm, Open-Label, Multicenter, Study of Folotyn® (Pralatrexate Injection) in Combination With Oral Leucovorin to Prevent or Reduce Mucositis in Patients With Hematological Malignancies Including PTCL and CTCL
Enrollment Status: Completed
Publish Date: November 20, 2019
Intervention Type: Drug
Study Phase: Phase 2
A Phase I/II Open-Label Dose-Finding Study of Ceritinib Combined With Brentuximab Vedotin for Front-Line Treatment of ALK-Positive Anaplastic Large Cell Lymphoma
A Phase I/II Open-Label Dose-Finding Study of Ceritinib Combined With Brentuximab Vedotin for Front-Line Treatment of ALK-Positive Anaplastic Large Cell Lymphoma
Enrollment Status: Withdrawn
Publish Date: October 10, 2019
Intervention Type: Drug, Other
Study Phase: Phase 1/Phase 2
Prospective Collection of Data in Pts With Peripheral T-Cell Lymphoma: PTCL,NOS;AITL; Extranodal NK/T-cell;Enteropathy-type; Hepatosplenic γ-δ; Subcutaneous Panniculitis-like; ALCL,Primary Systemic Type. By the Intl. T-Cell Lymphoma Project
Prospective Collection of Data in Pts With Peripheral T-Cell Lymphoma: PTCL,NOS;AITL; Extranodal NK/T-cell;Enteropathy-type; Hepatosplenic γ-δ; Subcutaneous Panniculitis-like; ALCL,Primary Systemic Type. By the Intl. T-Cell Lymphoma Project
Enrollment Status: Completed
Publish Date: July 08, 2019
View 7 Less Clinical Trials

96 Total Publications

Brentuximab vedotin plus chemotherapy for the treatment of front-line systemic anaplastic large cell lymphoma: subgroup analysis of the ECHELON-2 study at 5 years' follow-up.
Brentuximab vedotin plus chemotherapy for the treatment of front-line systemic anaplastic large cell lymphoma: subgroup analysis of the ECHELON-2 study at 5 years' follow-up.
Journal: Blood cancer journal
Published: September 05, 2024
Similar Doctors
Advanced in Nodular Lymphocyte-Predominant Hodgkin Lymphoma (NLPHL)
Dr. Farnoush A. Abar
Hematology Oncology | Hematology | Oncology
Advanced in Nodular Lymphocyte-Predominant Hodgkin Lymphoma (NLPHL)
Dr. Farnoush A. Abar
Hematology Oncology | Hematology | Oncology
825 Eastlake Ave E, 
Seattle, WA 
 (0.1 miles away)
206-520-5000
Languages Spoken:
English, Farsi, Spanish, Swahili
See accepted insurances
Accepting New Patients
Offers Telehealth

Farnoush Abar is a Hematologist Oncology specialist and a Hematologist in Seattle, Washington. Dr. Abar is rated as a Distinguished provider by MediFind in the treatment of Nodular Lymphocyte-Predominant Hodgkin Lymphoma (NLPHL). Her top areas of expertise are Waldenstrom Macroglobulinemia, Paget Disease of the Breast, Familial Pancreatic Cancer, and Pleuropulmonary Blastoma. Dr. Abar is currently accepting new patients.

Experienced in Nodular Lymphocyte-Predominant Hodgkin Lymphoma (NLPHL)
Dr. Sheldon Z. Goldberg
Hematology Oncology
Experienced in Nodular Lymphocyte-Predominant Hodgkin Lymphoma (NLPHL)
Dr. Sheldon Z. Goldberg
Hematology Oncology
1221 Madison Street, Suite 1020, 
Seattle, WA 
 (1.2 miles away)
206-991-2040
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Sheldon Goldberg is a Hematologist Oncology provider in Seattle, Washington. Dr. Goldberg is rated as an Advanced provider by MediFind in the treatment of Nodular Lymphocyte-Predominant Hodgkin Lymphoma (NLPHL). His top areas of expertise are Waldenstrom Macroglobulinemia, Monoclonal Gammopathy of Undetermined Significance (MGUS), Schnitzler Syndrome, Factor V Leiden Thrombophilia, and Bone Marrow Aspiration. Dr. Goldberg is currently accepting new patients.

Experienced in Nodular Lymphocyte-Predominant Hodgkin Lymphoma (NLPHL)
Dr. Andrea L. Veatch
Hematology Oncology | Oncology | Hematology
Experienced in Nodular Lymphocyte-Predominant Hodgkin Lymphoma (NLPHL)
Dr. Andrea L. Veatch
Hematology Oncology | Oncology | Hematology

Northwest Medical Specialties PLLC

1624 S I St, 
Tacoma, WA 
 (26.8 miles away)
253-428-8700
Languages Spoken:
English, French, Konkani, Malayalam, Spanish, Turkish, Vietnamese
See accepted insurances
Accepting New Patients
Offers Telehealth

Andrea Veatch is a Hematologist Oncology specialist and an Oncologist in Tacoma, Washington. Dr. Veatch is rated as a Distinguished provider by MediFind in the treatment of Nodular Lymphocyte-Predominant Hodgkin Lymphoma (NLPHL). Her top areas of expertise are Lung Cancer, Pleuropulmonary Blastoma, Dehydration, and Testicular Yolk Sac Tumor. Dr. Veatch is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Shustov's expertise for a condition
ConditionClose
View All 16 Advanced Conditions
View All 28 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile